BiotechTube
Agendia

Agendia

Amsterdam, Netherlands· Est.
agendia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $397M

Overview

Agendia is a commercial-stage diagnostics company specializing in genomic profiling for early-stage breast cancer. Its core offerings, MammaPrint and BluePrint, analyze tumor biology from a single sample to predict recurrence risk and identify molecular subtypes, aiming to personalize treatment and reduce both under- and over-treatment. Founded in 2005 and headquartered in Amsterdam, the company serves a global market, with its tests supported by extensive clinical validation and inclusion in major oncology guidelines. Agendia operates as a private company, generating revenue from its diagnostic testing services.

OncologyBreast Cancer

Technology Platform

Microarray and NGS-based genomic profiling for breast cancer. Flagship products are the MammaPrint 70-gene recurrence risk assay and the BluePrint 80-gene molecular subtyping assay, used together from a single sample.

Funding History

11
Total raised:$397M
Debt$20M
Debt$25M
Series E$50M
Series D$35M

Opportunities

The global shift towards precision oncology and value-based care creates strong demand for validated genomic tests that personalize treatment.
Expansion into international markets and demonstration of utility for guiding newer targeted therapies (e.g., CDK4/6 inhibitors) represent significant growth avenues.
Ongoing inclusion in major clinical guidelines like NCCN drives standard-of-care adoption.

Risk Factors

Intense competition from larger, well-funded diagnostics companies (e.g., Exact Sciences, Myriad Genetics) poses a major market share threat.
Reimbursement rates and coverage policies are subject to change and downward pressure, impacting revenue.
Rapid technological evolution in genomics could lead to disruptive new testing methodologies.

Competitive Landscape

Agendia competes in the crowded breast cancer genomic testing market. Key direct competitors include Exact Sciences (Oncotype DX) and Myriad Genetics (EndoPredict), which offer prognostic tests for hormone receptor-positive disease. Agendia differentiates with its rapid, combined risk and subtyping report from a single sample and its strong foundation in clinical trial data. It also faces competition from broader pan-cancer profiling companies like Foundation Medicine.

More companies in Diagnostics & Precision Medicine →More companies in Netherlands →